Back to search results

Ruxolitinib in Thrombocythemia and Polycythemia Vera

Abroad (travel likely)RecruitingPHASE2

Conditions

Essential Thrombocythemia · Polycythemia Vera

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • Massachusetts General Hospital, Boston, Massachusetts, United States

    Contact: Study coordinator (Gabriela Hobbs, MD) · ghobbs@partners.org · (617) 726-8748
    Contact: Principal Investigator (Gabriela Hobbs, MD)

  • Beth-Israel Deaconess Medical Center, Boston, Massachusetts, United States

    Contact: Study coordinator (Jeffrey Zwicker, MD) · jwicker@bidmc.harvard.edu · (617) 667-9920
    Contact: Principal Investigator (Jeffrey Zwicker, MD)

  • Dana Farber Cancer Institute, Boston, Massachusetts, United States

    Contact: Study coordinator (Marlise Luskin, MD) · Marlise_Luskin@DFCI.HARVARD.EDU · (617) 632-1906
    Contact: Principal Investigator (Marlise Luskin, MD)

  • Massachusetts General North Shore Cancer Center, Danvers, Massachusetts, United States

    Contact: Study coordinator (Michelle H. Lee, MD) · mlee37@mgb.org
Study leads

  • Gabriela Hobbs, MD

    Principal Investigator

    Massachusetts General Hospital

View source on ClinicalTrials.gov(opens in a new tab)